ReviewPregnancy (Hoboken, N.J.)2025
Quantifying prenatal and postnatal mortality in extreme early onset fetal growth restriction: A systematic review and incidence analysis.
Review in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Extreme early-onset fetal growth restriction (EE-FGR) is associated with significant perinatal morbidity and mortality. As short- and long-term prognoses are influenced by both gestational age and severity of FGR, quantifying risk is inherently challenging. We hypothesized that a meta-analysis would provide quantifiable estimates of perinatal outcomes in pregnancies complicated by EE-FGR. Methods: We searched PubMed, Scopus, Embase, and Web of Science databases for relevant studies published from inception to March 2024. We included all original studies involving singleton pregnancies with estimated fetal weights (EFWs) or abdominal circumferences < third centile or EFWs < 600 g, between 20 + 0 and 26 + 6 weeks of gestation. Studies were limited to fetuses with no known chromosomal, genetic, or major structural abnormalities. The National Institute of Health Quality Assessment Tool was utilized for the risk of bias assessment. Incidence meta-analyses were performed with proportions (percentages) calculated for each outcome using a random-effects model. Results: Five cohort studies (three prospective and two retrospective), comprising a total of 614 pregnancies, were included in the review. Two studies had overlapping populations; in such cases, the study containing the most relevant variables was selected for analysis. Four studies demonstrated good quality, and one was of fair quality. Pregnancy loss occurred at a rate of 39% (95% confidence interval [CI]: 29%-49%). Among live births, neonatal death was observed in 14% (95% CI: 4%-24%). Preterm birth (<37 weeks) was reported in 68% of cases (95% CI: 40%-96%), with very preterm birth (<32 weeks) accounting for 61% (95% CI: 34%-88%) of these, and extreme preterm birth (<28 weeks) comprising 25%. Additionally, 29% (95% CI: 20%-39%) of pregnancies were complicated by preeclampsia and/or hemolysis, elevated liver enzyme levels, and low platelet levels (HELLP) syndrome, with high heterogeneity ( Conclusion: Our meta-analyses quantitated the incidence of adverse fetal, neonatal, and maternal outcomes with EE-FGR, with the risk of pregnancy loss or neonatal death approaching nearly 50%, and among survivors, more than two thirds were born preterm. These findings provide valuable data for counseling families facing EE-FGR, though high heterogeneity highlights the need for further research. Trial Registration: PROSPERO database [CRD42019120930].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.